From: BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
Drug
Target
Dosage
Vemurafenib (Vem)
BRAF V600E
3 μM
Panitumumab (Pan)
EGFR wt
8 μg/mL
Afatinib (Afa)
TKI (EGFR wt/mut and ERBB2[HER2-Neu])
0.01, 0.1, 1, 10 μM